CARSON BURNS: Open Payments
NPI 1083299366 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,472 in 71 payments from 31 companies in 2025. Trend: 2023 $384 · 2024 $526 · 2025 $1,472
Food & beverage: $1,472
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $304 |
| Merck Sharp & Dohme LLC | 9 | $151 |
| Myriad Genetic Laboratories, Inc. | 1 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $90 |
| Janssen Biotech, Inc. | 4 | $87 |
| AstraZeneca Pharmaceuticals LP | 2 | $55 |
| Incyte Corporation | 3 | $53 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $48 |
| TerSera Therapeutics LLC | 2 | $44 |
Products named: KEYTRUDA, IMBRUVICA, MYRISK, ELAHERE, DATROWAY, Nubeqa, VENCLEXTA, MONJUVI.
Industry payments across MO — which companies pay providers there.
